Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease

Table 1 In situ expression of PGs in different gastric mucosa

	N	Positive rate	P value			Strongly-positive rate	P value			in situ PGI/II ratio^a	P value
			vs. NOR	vs. GS	vs. GA		vs. NOR	vs. GS	vs. GA		vs. NOR	vs. GS	vs. GA
In situ PGI expression
NOR	30	100.00%				50.00%				1.0(0.7,1.1)
GS	70	100.00%	/			32.90%	0.021 ^b			1.0(0.7,1.4)	0.292^d
GA	54	83.30%	0.023 ^c	<0.001 ^c		3.70%	<0.001 ^b	<0.001 ^b		0.8(0.4,1.1)	0.086^d	0.005 ^d
GC	31	0.00%	<0.001 ^b	<0.001 ^b	<0.001 ^b	0.00%	<0.001 ^b	<0.001 ^b	<0.001 ^b	0.0(0.0,0.0)	<0.001 ^d	<0.001 ^d	<0.001 ^d
In situ PGII expression
NOR	30	100.00%				63.30%				/
GS	70	100.00%	/			31.40%	0.015 ^b			/
GA	54	92.60%	0.291^c	0.034 ^c		1.90%	<0.001 ^b	<0.001 ^b		/
GC	31	0.00%	<0.001 ^b	<0.001 ^b	<0.001 ^b	0.00%	<0.001 ^b	<0.001 ^b	<0.001 ^b	/

^a, the ratios of PGI IRS to PGII IRS were represented as median (25%, 75%); ^b, the positive rates and strongly-positive rates of PGI and PGII staining in different gastric diseases were compared by Pearson's Chi-square test; ^c, the positive rates of PGI and PGII expression in different gastric diseases were determined by Fisher’s exact test; ^d, the in situ PGI/II ratios among multiple gastric diseases were first tested by Kruskal–Wallis test. If the result was indicated as statistically significant, the Mann–Whitney test was performed to further test the different between two groups. Analyses results with P < 0.05 were highlighted in bold characters.

ISSN: 1472-6890